GSK Investigational Site
Mexico City, 14050, Mexico
NCT Number: NCT00376038
GSK189075 is intended for use as a single treatment or in combination with other treatments for tye 2 diabetes mellitus (T2DM). Metformin is widely used in Europe and the USA for the treatment of T2DM. This study will evaluate the effect of GSK189075 on metformin levels in the blood in T2DM subjects. The rationale is to look for any safety problems that may result when the 2 drugs are given together.
Looking for future studies?
Notify Me30 year–64 year
All sexes
Interventional
Phase 1
Mexico City, 14050, Mexico
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: GSK189075 oral tablets
GlaxoSmithKline
Industry
A Randomized Open-label, Repeat Dose, Two Sequence Cross-Over Study to Determine the Effect of GSK189075 on the Pharmacokinetic Parameters of Metformin (Glucophage) in Subjects With Type 2 Diabetes Mellitus.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03620773
Adolescent Obesity, Bariatric Surgery Candidate
Aurora, Colorado, United States
View Trial DetailsNCT03899883
Diabetes, Diabetes Complications
Aurora, Colorado, United States
View Trial DetailsNCT04627103
Body Weight, Diabetes Mellitus
Halifax, Nova Scotia, Canada
View Trial DetailsNCT05472272
Body Weight, Body Weight Changes
Shanghai, Shanghai Municipality, China
View Trial Details